Analysed MILESTONE PHARMACEUTICALS IN (MIST:NASDAQ) News Sources
Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT
10-04-2026
yahoo.com
Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
07-04-2026
yahoo.com
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02-04-2026
yahoo.com
Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies
31-03-2026
yahoo.com
Milestone Pharmaceuticals Inc (MIST) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ...
20-03-2026
yahoo.com
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT
20-03-2026
yahoo.com
Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session
16-03-2026
yahoo.com
What is the current price of MILESTONE PHARMACEUTICALS IN (MIST:NASDAQ)?
The current price of MILESTONE PHARMACEUTICALS IN (MIST:NASDAQ) is $2.02.
MILESTONE PHARMACEUTICALS IN (MIST:NASDAQ) absolute price change since previous trading day?
The absolute price change of MILESTONE PHARMACEUTICALS IN (MIST:NASDAQ) since the previous trading day is $0.01.
MILESTONE PHARMACEUTICALS IN (MIST:NASDAQ) percentage price change since previous trading day?
The percentage price change of MILESTONE PHARMACEUTICALS IN (MIST:NASDAQ) since the previous trading day is 0.4975%.
What is the most recent average sentiment score for MILESTONE PHARMACEUTICALS IN (MIST:NASDAQ)?
The most recent average sentiment score for MILESTONE PHARMACEUTICALS IN (MIST:NASDAQ) is 79 out of 100.
What is the most recent average sentiment for MILESTONE PHARMACEUTICALS IN (MIST:NASDAQ)?
The most recent sentiment for MILESTONE PHARMACEUTICALS IN (MIST:NASDAQ) is .
SEC-8K** Filing Available For MILESTONE PHARMACEUTICALS IN (MIST:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.